CALT Calliditas Therapeutics Gross Profitability

Official company branding of Calliditas Therapeutics (CALT)

Calliditas Therapeutics (CALT) is developing an ecosystem for rare kidney pathologies, retaining customers through its drug Tarpeyo. Cloud-based algorithms in testing are driving efficiency growth, while strong management remains focused on global expansion. The gross income percentage on the GURU.Markets chart demonstrates business transparency, while the 93.50 metric confirms the company's current margin levels.

CALT: Calliditas Therapeutics Gross Margin 07/04/2022 - 09/28/2024

Financial and market metric breakdowns for Calliditas Therapeutics (CALT)

- market value and analyst target forecast:
Summary company analysis:Calliditas Therapeutics - CALT
Brand item of Calliditas

Conservative capital demands absolute transparency regarding operational efficiency to confirm business sustainability. This indicator measures the portion of revenue free from direct production costs, allowing risk managers to instantly identify any profitability dips. As Calliditas Therapeutics (CALT) expands the distribution of its IgA nephropathy treatments in the US and Europe, the dynamics of these costs are clearly reflected in the adjusted gross margin.